Extracellular Matrix and Immune Niches in Human Disease 2022View this Special Issue
PCSK9 Modulates Macrophage Polarization-Mediated Ventricular Remodeling after Myocardial Infarction
Background and Aims. An increasing number of high-risk patients with coronary heart disease (similar to acute myocardial infarction (AMI)) are using PCSK9 inhibitors. However, whether PCSK9 affects myocardial repair and the molecular mechanism of PCSK9 modulation of immune inflammation after AMI are not known. The present research investigated the role of PCSK9 in the immunomodulation of macrophages after AMI and provided evidence for the clinical application of PCSK9 inhibitors after AMI to improve cardiac repair. Methods and Results. Wild-type C57BL6/J (WT) and PCSK9-/- mouse hearts were subjected to left anterior descending (LAD) coronary artery occlusion to establish an AMI model. Correlation analysis showed that higher PCSK9 expression indicated worse cardiac function after AMI, and PCSK9 knockout reduced infarct size, improved cardiac function, and attenuated inflammatory cell infiltration compared to WT mice. Notably, the curative effects of PCSK9 inhibition were abolished after the systemic depletion of macrophages using clodronate liposomes. PCSK9 showed a regulatory effect on macrophage polarization in vivo and in vitro. Our studies also revealed that activation of the TLR4/MyD88/NF-κB axis was a possible mechanism of PCSK9 regulation of macrophage polarization. Conclusion. Our data suggested that PCSK9 modulated macrophage polarization-mediated ventricular remodeling after myocardial infarction.
Proprotein convertase subtilisin/kexin9 (PCSK9) is the ninth member of the proprotein convertase family, and it has a specialized function of targeting LDL receptor (LDLR) for degradation [1, 2]. The present study showed that the liver synthesized most circulating PCSK9 in peripheral blood . The PCSK9-LDLR complex is transported to the lysosome for degradation and prevents the LDLR from recycling to the cell membrane . Therefore, the functions of PCSK9 in lipoprotein metabolism have attracted increasing attention [5, 6]. Beyond that, PCSK9 has been detected in various tissues in the body, such as the lung , brain, and heart . More and more studies concentrated on the role of PCSK9 beyond plasma LDL regulation. In recent years, many studies have found that PCSK9 inhibitors not only can effectively reduce LDL but also are related to early plaque formation, late plaque rupture, thrombosis, and angiogenesis . Sun et al.  indicated that PCSK9 interacts with apolipoprotein B and prevents its intracellular degradation irrespective of the low-density lipoprotein receptor. A clinical trial showed that independently of LDL plasma levels, PCSK9 levels correlate with an elevated probability of future cardiovascular events . Many researchers also found that PCSK9 modulated inflammation levels [12, 13] and regulated the levels of inflammatory markers of macrophages, such as Arg-1 and IL10 . Clinical analysis showed that PCSK9 levels correlate with white blood cell count in patients with stable coronary artery disease  and PCSK9 affected rheumatoid arthritis and sepsis [15, 16].
Acute myocardial infarction (AMI) is one of the most common reasons for death and heart failure worldwide . In AMI, reduced blood flow to a region of the myocardium led to a region of mechanical weakness . Scar deposition was needed to prevent myocardial rupture and limit functional deterioration in this mechanical weakness myocardium . In the early stage of AMI, this adaptive remodeling is necessary. However, excessive and progressive ventricular remodeling would alter the ventricular structure and cardiac function and eventually lead to the clinical syndrome of HF (heart failure) . The main feature of the intense inflammatory reactions triggered by AMI is the infiltration of leukocytes into the infarcted heart . Numerous studies demonstrated that highly focused inflammatory reactions in infarcted hearts are the main causes of severe complications, including postinfarction heart failure and cardiac rupture [22–24]. Maintaining the balance of adaptive and maladaptive remodeling is very important for the prevention of complications after AMI . Macrophages are pleiotropic cells in the innate immune system and play central roles in the initial inflammatory response to injury and subsequent healing of tissue damaged by ischemia. Macrophages are generally classified into two major subsets: the inflammatory M1 type and the anti-inflammatory M2 type . M1 macrophages are characterized by the secretion of proinflammatory cytokines and growth factors and typically facilitate degradation of the extracellular matrix and remove cell debris during the early phase of myocardial infarction [27, 28]. However, the prolonged presence of M1 macrophages leads to excessive or persistent inflammation and expansion of the infarction area . In contrast, M2 macrophages are characterized by the secretion of anti-inflammatory and reparative factors that facilitate angiogenesis and repair myocardial lesions . Therefore, switching the macrophage phenotype from M1 to M2 is a promising approach to identifying novel therapeutic targets for myocardial repair after myocardial infarction [31–33].
With the wide use of PCSK9 inhibitors in high-risk patients with coronary heart disease (e.g., AMI), researchers are increasingly interested in whether PCSK9 affects myocardial repair after AMI. Emerging evidence indicated that PCSK9 was upregulated in ischemic myocardium and determined the development of infarct size, heart function, and autophagy. However, some studies found that PCSK9 deficiency impacted cardiac lipid metabolism and contributed to the development of HFpEF (HF with preserved ejection fraction) . Therefore, our research further examined the relationship between PCSK9 expression and cardiac function after AMI. The results suggested that PCSK9 gene and protein expression was significantly increased after AMI, and high PCSK9 levels indicated poor cardiac function. The inhibition of highly expressed PCSK9 improved cardiac function. To examine the correlating mechanism, we injected clodronate liposomes to clear systemic macrophages in mice. Notably, the curative effects of PCSK9 inhibition were abolished after macrophage depletion. Based on these research results, we hypothesized that high PCSK9 expression after AMI would lead to poor myocardial repair by promoting M1 macrophage polarization. Inhibition of PCSK9 expression may induce switching of the macrophage phenotype from M1 to M2 and promote myocardial repair after infarction.
2. Materials and Methods
C57BL/6 wild-type mice were purchased from Jiangsu Jicui Yaokang Animal Corp. PCSK9 heterozygous mice on a C57BL/6 background were kindly provided by Dr. Lu Xifeng (Shenzhen University, China) and purchased from the Jackson Laboratory (number 005993-PCSK9tm1Jdh). Colonies were maintained by intercrossing heterozygous mutant mice to generate PCSK9+/+ and PCSK9-/- mice. All laboratory animal experiments and maintenance procedures were approved by the Institutional Ethics Committee of Guangdong Pharmaceutical University.
2.2. Animal Experimental Protocol
Only 10-week-old male mice were used in our study. To create an AMI state, WT and PCSK9-/- mice were anesthetized via 1.5% isoflurane inhalation, and the left anterior descending branch (LAD) was ligated using 7-0 silk suture. The LAD was only threaded in the sham group and was not ligated. The mice were euthanized at 7 days, and the hearts were collected for further examination. To study the role of macrophages, clodronate liposomes were injected (150 μL, 5 mg/mL) (Liposoma BV, NL) into the mouse tail vein 24 h before and after the artery ligation surgery, and mice in the control group were injected with PBS.
Seven days after surgery, ecthocardiography was performed to assess the left ventricular function of the mice in each group. We used a 12 MHz probe (VisualSonics Vevo 2100, Canada) to perform M-mode and B-mode echocardiography on mice anesthetized via isoflurane (1%) inhalation. The left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (FS%) were quantified as ; LV end-systolic diameter (LVIDs) and LV end-diastolic diameter (LVIDd) were measured.
2.4. ELISA of PCSK9
A mouse PCSK9 ELISA kit (BOSTER, China) was used to measure the PCSK9 levels in peripheral blood that was collected 7 days after surgery.
2.5. Histological and Immunohistochemical Analysis
Mice were sacrificed with injections of 1% sodium pentobarbital into the cavum abdominis. The chest was opened quickly, perfused, and fixed with 4% paraformaldehyde. 4% paraformaldehyde was used to fix the hearts overnight; then, the hearts were sectioned for H&E staining, immunohistochemical analysis, and Masson trichrome histopathology analyses. The cardiac macrophage population was stained with the macrophage marker F4/80 (Abcam, ab100790, UK). Macrophage polarization marker CD206 and iNOS immunofluorescence antibodies were purchased from Abcam (ab64693, ab3523, UK), and F4/80 antibody was provided by Servicebio (GB11027, China).
2.6. Cell Culture and Treatments
Mouse RAW264.7 cells (Procell Life Science & Technology, China) were cultured in 10% FBS high-glucose complete DMEM in 95% air and 5% CO2 at 37°C. The RAW264.7 cells were stimulated for 12 h with 1 ng/mL LPS (Sigma, L2880, USA) and for 24 h with 20 ng/mL IL4 (Sigma, SRP3211, USA) to induce M1 macrophage and M2 macrophage differentiation respectively. To investigate the effects of PCSK9 on macrophage polarization, recombinant mouse PCSK9 protein (500 ng/mL) (Novoprotein, CA86, China) was added to polarized RAW264.7 cells for 24 h. To further analyze whether TLR4 is involved in PCSK9-regulated macrophage polarization, cells were pretreated with TLR4 inhibitor (TAK-242, 20 nM) (Sigma, A3850, USA) for 6 h.
2.7. Western Blot Analysis
Protein from the mouse hearts and RAW264.7 cells was prepared using a RIPA lysis buffer system (Santa Cruz, CA, USA). A BCA protein assay kit was used to determine the quantity of the protein samples. After the proteins were transferred to a polyvinylidene fluoride membrane and blocking with 5% nonfat milk for 2 h, the membranes were incubated overnight with primary antibody at 4°C, then incubated with a secondary antibody (goat anti-rabbit IgG) for 1 h after washing with TBST. Signals were detected using a Bio-Rad Gel Doc EZ imaging system (Gel Doc EZ Imager, CA, USA). The following primary antibody information was used: PCSK9 (Abcam, ab32727, US), IL6 (CST, 12912, USA), TNF-α (CST, 11948, USA), iNOS (CST, 13120, USA), TGF-β (CST, 41896, USA), TLR4 (CST, 14358, USA), MyD88 (CST, 4283, USA), and NF-κB (CST, 3036, USA).
2.8. Real-Time Quantitative PCR
RNA was extracted from mouse hearts and RAW264.7 cells using the TRIzol reagent and reverse-transcribed using SuperScript II (Life Technologies, USA) at 42°C. The expression of each gene of interest was measured using SYBR Green PCR core reagents (Applied Biosystems). GAPDH was used as an internal mRNA standard, and the 2–ΔΔCT method was used to measure the relative expression levels of each gene. Primers were designed according to the following GenBank database information: IL6 (AAGTCCGGAGAGGAGACTTC TGGATGGTCTTGGTCCTTAG), TGF-β (CGGAGAGCCCTGGATACCA CGGAGAGCCCTGGATACCA), iNOS (TCACCTTCGAGGGCAGCCGA TCCGTGGCAAAGCGAGCCAG), CD206 (CTGCAGATGGGTGGGTTATT GGCATTGATGCTGCTGTTATG), GAPDH (AGAACATCATCCCTGCCTCTACT GATGTCATCATATTTGGCAGGTT), and PCSK9 (ATGAGCAGTGACCTGTTGGG TGGGCGAAGACAAAGGAGTC).
2.9. Flow Cytometry Analysis
Flow cytometry of three fluorescence markers was used to count the percentages of M1 and M2 macrophages in each group after the cells were treated with LPS or IL4 and recombinant mouse PCSK9 protein. M1 macrophages were identified as F4/80+/iNOS+/CD206- cells, and M2 macrophages were identified as F4/80+/iNOS-/CD206+ cells. After these experimental steps, the RAW264.7 cells were digested into a single-cell suspension at a density of cells/mL. A 100 μL cell suspension was incubated with fluorescent antibodies (anti-F4/80, anti-iNOS, and anti-CD206) at 4°C for 1 h. The cells were immediately analyzed using flow cytometry. The following primary antibodies were used: CD206 and iNOS immunofluorescence antibodies were purchased from Abcam (ab64693,ab3523, USA), and F4/80 antibodies were provided by Servicebio (GB11027, China).
3. Statistical Analysis
Data from at least three independent experiments are presented as the , and significant differences between two groups were determined using unpaired -tests. One-way analysis of variance (ANOVA) was used to assess the differences between multiple comparisons followed by Tukey’s multiple comparisons test. Two different interventions between multiple comparisons were tested using two-way ANOVA followed by Bonferroni’s multiple comparisons test. GraphPad Prism software was used to perform all analyses, and a value less than 0.05 was considered statistically significant.
4.1. Overexpression of PCSK9 in Myocardial Tissue and Peripheral Mouse Blood after AMI
To clarify the changes in PCSK9 expression after myocardial infarction, q-PCR and ELISA were performed. The ELISA analysis showed that the expression of PCSK9 in peripheral mouse blood was increased in the WT ischemia group compared to the control group and WT sham group () (Figure 1(a)). The results also showed that PCSK9 mRNA expression in the WT ischemia group was obviously increased compared to the control group and WT sham group () (Figure 1(b)). To further understand the relationship between PCSK9 expression and cardiac function after AMI, EF% and LVIDd were measured using echocardiography 7 d after AMI (Figure 1(c)), and the correlation between these factors was calculated. The results showed that PCSK9 expression is negatively correlated with the LVEF () and positively correlated with the LVIDs () (Figure 1(d)). Taken together, the data showed that the expression of PCSK9 increased significantly after AMI in mice. The correlation analysis indicated a significant correlation between PCSK9 expression and cardiac function after myocardial infarction.
4.2. Inhibition of Highly Expressed PCSK9 Reduced Infarct Size and Inflammation and Improved Heart Function after AMI in Mice
To inquire about the role of PCSK9 in myocardial injury, we constructed PCSK9-knockout mice. Seven days after LAD artery ligation surgery, we compared the infarct size, inflammation, echocardiographs, and myocardial fibrosis of the mice in the WT and PCSK9-/- ischemia groups. The results of echocardiography showed that LVEF ( vs. ) (Figures 2(a) and 2(b)) and LVFS ( vs. ) (Figures 2(a) and 2(b)) in the PCSK9-/- ischemia group were significantly higher than that in the WT ischemia group. The LVIDd ( vs. ) (Figures 2(a) and 2(c)) and LVIDs ( vs. ) (Figures 2(a) and 2(c)) were lower than that in the WT ischemia group (). The results of TTC staining showed that the infarct size was obviously smaller in the PCSK9-/- ischemia group ( vs. ) (Figure 2(d)). Masson staining was used to evaluate the extent of myocardial fibrosis and indicated that the collagen density in the infarcted area of the PCSK9-/- ischemia group was obviously decreased compared to the WT ischemia group ( vs. ) (Figures 2(e) and 2(f)). HE staining of myocardial tissue showed that a large number of inflammatory cells infiltrated the WT ischemia group myocardium compared to the WT sham group, but the number of inflammatory cells decreased notably when PCSK9 expression was knocked down ( vs. ) (Figure 2(g)). These figures suggested that inhibition of highly expressed PCSK9 after AMI reduced the infarct size, myocardial fibrosis, and inflammatory response and promoted cardiac function repair after acute myocardial infarction.
4.3. Systemic Depletion of Macrophages Reduced the Benefits of PCSK9 Knockout in Cardiac Repair after Myocardial Infarction
The role of macrophages in the modulation of cardiac inflammation after AMI was explored in recent years, but the relationship between macrophages and the effects of PCSK9 on the modulation of cardiac function after AMI are not clear. To examine this relationship, we injected clodronate liposomes into the mouse tail vein 24 h before and after the artery ligation surgery (Figure 3(a)). The results showed that clodronate liposomes significantly reduced the cardiac macrophage population, as indicated by the F4/80 macrophage marker level in immunohistochemistry analyses (Figure 3(b)). After clodronate liposome injection, we found that cardiac function was not significantly different between the Cl2MDP-treated and PBS-treated WT ischemia groups in LVEF ( vs. ) or LVIDs ( vs. ) (Figures 3(c) and 3(d)). Clodronate liposomes did not aggravate ischemic injury. However, clodronate liposomes attenuated the benefits of PCSK9 gene knockout, as indicated by the worsened cardiac function. Cardiac function was significantly worse in the Cl2MDP-treated group than in the PBS-treated PCSK9-/- ischemia group, including LVEF ( vs. ) and LVIDs ( vs. ) (Figures 3(e) and 3(f)). These results showed that depletion of macrophages attenuated the benefits of PCSK9 gene knockout after myocardial infarction. Therefore, cardiac macrophages were required for the effects of PCSK9 on infarction repair.
4.4. PCSK9 Knockout Inhibited M1 Polarization and Promoted M2 Polarization in Myocardial Macrophages after Infarction
Macrophages exhibit distinct subtypes and polarization statuses after infarction. On the basis of our results, we investigated the function of PCSK9 on cardiac macrophage polarization in mice after infarction. The proportions of M1 (F4/80+iNOS+CD206-) and M2 (F4/80+iNOS-CD206+) macrophages were measured using immunofluorescence staining of the myocardium. The results showed that the proportion of M2 macrophages was increased compared to the WT ischemia group ( vs. ) (Figure 4(a)), and the proportion of M1 macrophages was decreased in the PCSK9-/- ischemia group ( vs. ) (Figure 4(a)). The results of the q-PCR and Western blot analyses showed that the expression of M1 macrophage markers (IL6, iNOS) was remarkably reduced in the PCSK9-/- ischemia group compared to the WT ischemia group (Figures 4(b)–4(d)), but the expression of M2 macrophage markers (TNF-β and CD206) was increased (Figures 4(b)–4(d)). Collectively, the results showed that PCSK9 knockout polarized macrophages from the M1-like phenotype toward the M2-like phenotype upon myocardial injury.
4.5. In Vitro, Exogenous PCSK9 Protein Induced Inflammatory Macrophages to Acquire the M1 Phenotype
To examine the effect of PCSK9 on macrophage polarization in vitro, recombinant mouse PCSK9 protein was added to polarized RAW264.7 cells stimulated with 1 ng/mL LPS and 20 ng/mL IL4 for 24 h (Figure 5(a)). The concentration grading experiment revealed that 0.5 μg/mL PCSK9 protein significantly induced IL6 expression in RAW264.7 cells and had no effect on cell viability (Figure 5(b)). The expression of M1 markers (IL6 and iNOS) and M2 markers (TGF-β and CD206) in cultured RAW264.7 cells was determined using q-PCR, Western blotting, and flow cytometry. Flow cytometry analysis showed that the proportion of M1 macrophages increased significantly () (Figures 5(c) and 5(d)), but there was no significant difference in the proportion of M2 macrophages () (Figures 5(c) and 5(d)) compared to the control group. The q-PCR results showed that PCSK9 mRNA addition increased the expression of IL6 and iNOS () (Figure 5(e)), but there were no significant differences in the expression of TGF-β and CD206 () (Figure 5(f)) compared to the control group. Western blot analysis also showed that M1 markers (IL6 and iNOS) increased significantly () (Figure 5(g)), but M2 markers (TGF-β and CD206) were not significantly different () (Figure 5(g)). These data showed that high expression of PCSK9 promoted M1 macrophage polarization in vitro.
4.6. PCSK9 Regulated M1 Macrophage Polarization by Targeting TLR4
In vivo and in vitro Western blot analyses showed that high expression ofPCSK9 significantly upregulated the TLR4/MyD88/NF-κB pathway. In vivo, the expression of the TLR4/MyD88/NF-κB pathway was upregulated in the WT ischemia group and downregulated in the PCSK9-/- ischemia group (Figures 6(a) and 6(b)). In vitro, after cocultivation with PCSK9 protein for 24 h, TLR4 and downstream MyD88/NF-κB were significantly upregulated in the LPS+mPCSK9 group compared with the LPS group. But there was no significant difference between the IL4 group and the IL4+mPCSK9 group (Figures 6(c) and 6(d)). To further analyze whether TLR4 is involved in PCSK9-regulated macrophage polarization, cells were pretreated with TLR4 inhibitor (TAK-242), TAK-242 is a small-molecule cyclohexene derivative, and it selectively binds to Cys-747 in the TIR (Toll/IL-1 receptor) domain of the intracellular receptor, which in turn hinders the downstream adaptor proteins (TRAM and TIRAP) from binding to TLR4 to totally suppress the pathway [35, 36]. Western blot was performed to detect levels of M1 macrophage markers IL-6 and iNOS. As shown in Figures 6(e) and 6(f), LPS was added to culture systems in order to induce an inflammatory microenvironment. With the presence of inhibitors TAK-242, the M1 macrophage markers iNOS and IL-6 induced by PCSK9 were suppressed and significantly lower than those without inhibitors (). Meanwhile, the presence of inhibitors TAK-242 significantly upregulates the level of the MyD88/NFκB pathway. The results suggested that TLR4 may be a key factor in PCSK9-regulated macrophage polarization.
Animal experiments previously showed that the plasma PCSK9 concentration was significantly increased in AMI . SREBP-2 and HNF1α are predominant transcription factors for PCSK9 and play important roles in the upregulation of PCSK9. PCSK9 gene and protein expression were significantly increased in the ischemia group 7 d after LAD ligation in our study, which was consistent with previous studies. The correlation analysis between these factors indicated that the PCSK9 level positively correlated with LVIDs and negatively correlated with LVEF. These data suggested that PCSK9 gene and protein expression were significantly increased after AMI, and a high PCSK9 level indicated poor cardiac function. Because of relatively small samples in linearity analysis, larger samples should be used in future studies, particularly clinical samples.
Another interesting finding of our research was that TGF-β, which is an important regulator of cardiac fibrosis, was upregulated in the PCSK9-/- group compared to the WT group after AMI, which was not completely consistent with the Masson staining results in our study. We hypothesized that the reason for this difference was that the role of TGF-β signaling in the infarcted myocardium always elicited complex and opposing cellular responses . Some studies showed that early TGF-β antagonism within 24 h following myocardial infarction led to increased mortality and enhanced proinflammatory cytokine and chemokine gene expression . In contrast, late TGF-β inhibition decreased collagen deposition after the infarct healing and meanwhile attenuated adverse remodeling . Therefore, TGF-β likely exerts different roles during different stages of myocardial infarction. Our research found that PCSK9 knockout provided better protection against myocardial injury by upregulating TGF-β and inducing M2 macrophage polarization. We will design experiments to further demonstrate the effects of PCSK9 in TGF-β modulation of fibroblast phenotype and fibrosis. What is the role of high expression of PCSK9 regarding the function and adaptation of cardiomyocytes? The Ding et al. study showed that hypoxia-induced PCSK9 expression in cardiomyocytes and expression of PCSK9 were dependent on the duration of hypoxia; what is more, PCSK9 secretion by cardiomyocytes causes the development of autophagy . According to the abovementioned results, we hypothesized that ischemia-hypoxia-induced cardiomyocytes in ischemic areas secreted PCSK9 which regulated macrophage switching to inflammatory M1 polarization. The macrophage/cardiomyocyte coculture system under hypoxia conditions will be designed to test this hypothesis in future studies.
The relationship between cardiac function after AMI and the levels of PCSK9 in peripheral blood has not been established in clinical studies. Wiviott et al. showed that PCSK9 inhibitors had different effects on different myocardial infarct subtypes . For example, evolocumab (PCSK9 monoclonal antibody) reduced the risk of spontaneous and procedural AMI but had no effect on type 2 (as indicated by a mismatch in myocardial oxygen supply and demand) AMI events . The ORION-4 trial will assess the effects of reduced PCSK9 levels in circulation on clinical outcomes . Recent studies showed that better outcomes were attributed to LDL-C level reduction . Our study is the first report to explain the possible mechanisms by which PCSK9 inhibition modulates the immunoregulatory functions of macrophages to promote heart repair after infarction. Through this study, we wanted to explore the causative role of PCSK9 in post-AMI ventricular remodeling and its potential as a therapeutic target for cardiac repair after AMI.
Macrophages play important roles in the extent and effect of inflammatory cell infiltration in the ischemic heart following AMI . Therefore, promotion of proinflammatory M1 macrophage switching to anti-inflammatory M2 macrophages after AMI may be a novel treatment for immune regulation . The exact mechanisms of macrophage polarization post-MI are not clear , and the sources of macrophages and the local microenvironment may explain the difficulty in determining the mechanism of macrophage phenotype switching [27, 46]. The microenvironment post-MI is filled with early proinflammatory M1 factors and anti-inflammatory M2 macrophages, which likely induce macrophage polarization [47, 48]. Previous studies showed that PCSK9 was a direct inflammatory mediator because PCSK9 increased the expression of proinflammatory cytokines, such as TNF-α and IL-6, in macrophages [49, 50]. Investigation into the regulatory function of PCSK9 in atherosclerosis showed that PCSK9 activated NF-κB signaling to promote inflammation . The inhibition of TLR4 and its downstream MyD88/NF-κB signaling pathway has been shown to alleviate inflammation by negatively polarizing M1 macrophages . Our research revealed that overexpression of PCSK9 in myocardium and macrophage both upregulated TLR4 and its downstream MyD88/NF-κB expression which also induced M1 macrophage polarization. With the presence of TLR4 inhibitors TAK-242, the M1 macrophage markers induced by PCSK9 were suppressed and significantly lower than those without inhibitors. These results demonstrated that PCSK9 induced M1 macrophage polarization by promoting the activation of the TLR4/MyD88/NF-κB pathway.
In summary, our findings suggest that high expression of PCSK9 after AMI leads to poor myocardial repair by regulating M1 macrophage polarization via TLR4/MyD88/NF-κB signaling. In contrast, PCSK9 knockout provides better protection against myocardial injury by inducing M2 macrophage polarization. However, deficiency of clinical data of patients who used PCSK9 inhibitor after AMI is the limitation of our research. The major reason is that there are only two monoclonal antibodies targeting PCSK9 available for treating hypercholesterolemia in clinic. They can obviously decrease LDL particles in blood without affecting plasma PCSK9 levels. In further studies, we will screen desirable PCSK9 small molecule inhibitors which can reduce plasma PCSK9 levels in vivo to reveal more PCSK9 functions in cardiovascular diseases beyond LDL-cholesterol plasma level regulation.
|PCSK9:||Proprotein convertase subtilisin kexin 9|
|LVIDd:||LV end-diastolic diameter|
|LVIDs:||LV end-systolic diameter|
|TLR4:||Toll-like receptor 4|
The data used to support the findings of this study are included within the article.
Animal experiments were executed with the approval of the Institutional Ethics Committee of Guangdong Pharmaceutical University.
Conflicts of Interest
The authors report no conflicts of interest.
Jun, Guo and Aidong, Zhang designed the study; Feifei, Wang; Min, Li; Hairui, Li; and Can Jiang performed the experiments and analyzed the data together. Feifei, Wang drafted the manuscript; all authors critically revised it. All authors approved the final manuscript and agreed to publish it in the Journal of Immunology Research.
We thank Dr. Lu Xifeng (Shenzhen University, China) for kindly providing the PCSK9 heterozygous mice on a C57BL/6 background. This work was supported by the Guangdong Medical Science and Technology Research Foundation (grant number (A2020210)).
Graphical Abstract: high PCSK9 expression after AMI would lead to poor myocardial repair by promoting M1 macrophage polarization; inhibition of PCSK9 expression may induce switching of the macrophage phenotype from M1 to M2 and promote myocardial repair after infarction. (Supplementary Materials)
A. W. Artenstein and S. M. Opal, “Proprotein convertases in health and disease,” The New England Journal of Medicine, vol. 365, no. 26, pp. 2507–2518, 2011.View at: Publisher Site | Google Scholar
M. Farnier, “PCSK9 : de la decouverte aux applications therapeutiques,” Archives of Cardiovascular Diseases, vol. 107, no. 1, pp. 58–66, 2014.View at: Publisher Site | Google Scholar
A. Zaid, A. Roubtsova, R. Essalmani et al., “Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration,” Hepatology: official journal of the American Association for the Study of Liver Diseases, vol. 48, no. 2, pp. 646–654, 2008.View at: Publisher Site | Google Scholar
J. Xiao, Y. M. Deng, X. R. Liu et al., “PCSK9: a new participant in lipophagy in regulating atherosclerosis?” Clinica chimica acta; international journal of clinical chemistry, vol. 495, pp. 358–364, 2019.View at: Publisher Site | Google Scholar
S. J. Nicholls, R. Puri, T. Anderson et al., “Effect of Eeolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial,” JAMA, vol. 316, no. 22, pp. 2373–2384, 2016.View at: Publisher Site | Google Scholar
M. S. Sabatine, R. P. Giugliano, A. C. Keech et al., “Evolocumab and clinical outcomes in patients with cardiovascular disease,” The New England Journal of Medicine, vol. 376, no. 18, pp. 1713–1722, 2017.View at: Publisher Site | Google Scholar
L. Fagerberg, B. M. Hallström, P. Oksvold et al., “Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics,” Molecular & cellular proteomics: MCP, vol. 13, no. 2, pp. 397–406, 2014.View at: Publisher Site | Google Scholar
Z. Ding, X. Wang, S. Liu et al., “PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy,” Cardiovascular Research, vol. 114, no. 13, pp. 1738–1751, 2018.View at: Publisher Site | Google Scholar
G. D. Norata, H. Tavori, A. Pirillo, S. Fazio, and A. L. Catapano, “Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering,” Cardiovascular Research, vol. 112, no. 1, pp. 429–442, 2016.View at: Publisher Site | Google Scholar
H. Sun, A. Samarghandi, N. Zhang, Z. Yao, M. Xiong, and B. B. Teng, “Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 7, pp. 1585–1595, 2012.View at: Publisher Site | Google Scholar
K. Leander, A. Mälarstig, F. M. Van’t Hooft et al., “Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors,” Circulation, vol. 133, no. 13, pp. 1230–1239, 2016.View at: Publisher Site | Google Scholar
Z. H. Tang, J. Peng, Z. Ren et al., “New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway,” Atherosclerosis, vol. 262, pp. 113–122, 2017.View at: Publisher Site | Google Scholar
C. Ricci, M. Ruscica, M. Camera et al., “PCSK9 induces a pro-inflammatory response in macrophages,” Scientific Reports, vol. 8, no. 1, p. 2267, 2018.View at: Publisher Site | Google Scholar
S. Li, Y. L. Guo, R. X. Xu et al., “Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease,” Atherosclerosis, vol. 234, no. 2, pp. 441–445, 2014.View at: Publisher Site | Google Scholar
N. Komatsu and H. Takayanagi, “Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints,” Frontiers in Immunology, vol. 3, p. 77, 2012.View at: Publisher Site | Google Scholar
A. Krabben, T. W. Huizinga, and A. H. Mil, “Biomarkers for radiographic progression in rheumatoid arthritis,” Current Pharmaceutical Design, vol. 21, no. 2, pp. 147–169, 2015.View at: Publisher Site | Google Scholar
D. Berliner, L. S. Maier, U. Wollenberg et al., “Clinical care for patients with recurrent myocardial ischemia in Germany-the VOICES trial,” Journal of Thoracic Disease, vol. 10, no. 15, p. S1777, 2018.View at: Publisher Site | Google Scholar
I. Visan, “Adipose tissue TM cells,” Nature Immunology, vol. 19, no. 2, p. 99, 2018.View at: Publisher Site | Google Scholar
M. Nahrendorf, “Myeloid cell contributions to cardiovascular health and disease,” Nature Medicine, vol. 24, no. 6, pp. 711–720, 2018.View at: Publisher Site | Google Scholar
F. K. Swirski and M. Nahrendorf, “Cardioimmunology: the immune system in cardiac homeostasis and disease,” Nature Reviews. Immunology, vol. 18, no. 12, pp. 733–744, 2018.View at: Publisher Site | Google Scholar
P. Christia and N. G. Frangogiannis, “Targeting inflammatory pathways in myocardial infarction,” European Journal of Clinical Investigation, vol. 43, no. 9, pp. 986–995, 2013.View at: Publisher Site | Google Scholar
X. M. Gao, D. A. White, A. M. Dart, and X. J. Du, “Post-infarct cardiac rupture: recent insights on pathogenesis and therapeutic interventions,” Pharmacology & Therapeutics, vol. 134, no. 2, pp. 156–179, 2012.View at: Publisher Site | Google Scholar
F. K. Swirski and M. Nahrendorf, “Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure,” Science, vol. 339, no. 6116, pp. 161–166, 2013.View at: Publisher Site | Google Scholar
S. D. Prabhu and N. G. Frangogiannis, “The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis,” Circulation Research, vol. 119, no. 1, pp. 91–112, 2016.View at: Publisher Site | Google Scholar
C. Peet, A. Ivetic, D. I. Bromage, and A. M. Shah, “Cardiac monocytes and macrophages after myocardial infarction,” Cardiovascular Research, vol. 116, no. 6, pp. 1101–1112, 2020.View at: Publisher Site | Google Scholar
Y. H. Zhang, M. He, Y. Wang, and A. H. Liao, “Modulators of the balance between M1 and M2 macrophages during pregnancy,” Frontiers in Immunology, vol. 8, p. 120, 2017.View at: Publisher Site | Google Scholar
X. Yan, A. Anzai, Y. Katsumata et al., “Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction,” Journal of Molecular and Cellular Cardiology, vol. 62, pp. 24–35, 2013.View at: Publisher Site | Google Scholar
E. N. ter Horst, N. Hakimzadeh, A. M. van der Laan, P. A. Krijnen, H. W. Niessen, and J. J. Piek, “Modulators of macrophage polarization influence healing of the infarcted myocardium,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 29583–29591, 2015.View at: Publisher Site | Google Scholar
F. Leuschner, P. Dutta, R. Gorbatov et al., “Therapeutic siRNA silencing in inflammatory monocytes in mice,” Nature Biotechnology, vol. 29, no. 11, pp. 1005–1010, 2011.View at: Publisher Site | Google Scholar
Y. Ma, A. J. Mouton, and M. L. Lindsey, “Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction,” Translational research: the journal of laboratory and clinical medicine, vol. 191, pp. 15–28, 2018.View at: Publisher Site | Google Scholar
T. Harel-Adar, T. Ben Mordechai, Y. Amsalem, M. S. Feinberg, J. Leor, and S. Cohen, “Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 5, pp. 1827–1832, 2011.View at: Publisher Site | Google Scholar
G. Courties, T. Heidt, M. Sebas et al., “In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing,” Journal of the American College of Cardiology, vol. 63, no. 15, pp. 1556–1566, 2014.View at: Publisher Site | Google Scholar
L. S. Zhou, G. L. Zhao, Q. Liu, S. C. Jiang, Y. Wang, and D. M. Zhang, “Silencing collapsin response mediator protein-2 reprograms macrophage phenotype and improves infarct healing in experimental myocardial infarction model,” Journal of Inflammation, vol. 12, no. 1, p. 11, 2015.View at: Publisher Site | Google Scholar
L. Da Dalt, L. Castiglioni, A. Baragetti et al., “PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction,” European Heart Journal, vol. 42, no. 32, pp. 3078–3090, 2021.View at: Publisher Site | Google Scholar
N. Matsunaga, N. Tsuchimori, T. Matsumoto, and M. Ii, “TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules,” Molecular Pharmacology, vol. 79, no. 1, pp. 34–41, 2011.View at: Publisher Site | Google Scholar
T. Kawamoto, M. Ii, T. Kitazaki, Y. Iizawa, and H. Kimura, “TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain,” European Journal of Pharmacology, vol. 584, no. 1, pp. 40–48, 2008.View at: Publisher Site | Google Scholar
Y. Zhang, J. Liu, S. Li et al., “Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat,” BMC Cardiovascular Disorders, vol. 14, no. 1, p. 192, 2014.View at: Publisher Site | Google Scholar
M. Bujak and N. G. Frangogiannis, “The role of TGF-beta signaling in myocardial infarction and cardiac remodeling,” Cardiovascular Research, vol. 74, no. 2, pp. 184–195, 2007.View at: Publisher Site | Google Scholar
M. Ikeuchi, H. Tsutsui, T. Shiomi et al., “Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction,” Cardiovascular Research, vol. 64, no. 3, pp. 526–535, 2004.View at: Publisher Site | Google Scholar
H. Okada, G. Takemura, K. Kosai et al., “Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure,” Circulation, vol. 111, no. 19, pp. 2430–2437, 2005.View at: Publisher Site | Google Scholar
S. D. Wiviott, R. P. Giugliano, D. A. Morrow et al., “Effect of evolocumab on type and size of subsequent myocardial infarction: a prespecified analysis of the Fourier randomized clinical trial,” JAMA Cardiology, vol. 5, no. 7, pp. 787–793, 2020.View at: Publisher Site | Google Scholar
H. D. White, P. G. Steg, M. Szarek et al., “Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial,” European Heart Journal, vol. 40, no. 33, pp. 2801–2809, 2019.View at: Publisher Site | Google Scholar
R. M. Stoekenbroek, G. Lambert, B. Cariou, and G. K. Hovingh, “Inhibiting PCSK9 -- biology beyond LDL control,” Nature Reviews. Endocrinology, vol. 15, no. 1, pp. 52–62, 2018.View at: Publisher Site | Google Scholar
I. Andreadou, M. Tsoumani, G. Vilahur et al., “PCSK9 in myocardial infarction and cardioprotection: importance of lipid metabolism and inflammation,” Frontiers in Physiology, vol. 11, article 602497, 2020.View at: Publisher Site | Google Scholar
W. Li, H. M. Hsiao, R. Higashikubo et al., “Heart-resident CCR2+ macrophages promote neutrophil extravasation through TLR9/MyD88/CXCL5 signaling,” JCI insight, vol. 1, no. 12, 2016.View at: Publisher Site | Google Scholar
I. Hilgendorf, L. M. Gerhardt, T. C. Tan et al., “Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium,” Circulation Research, vol. 114, no. 10, pp. 1611–1622, 2014.View at: Publisher Site | Google Scholar
P. Christia, M. Bujak, C. Gonzalez-Quesada et al., “Systematic characterization of myocardial inflammation, repair, and remodeling in a mouse model of reperfused myocardial infarction,” The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society, vol. 61, no. 8, pp. 555–570, 2013.View at: Publisher Site | Google Scholar
M. Jung, Y. Ma, R. P. Iyer et al., “IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation,” Basic Research in Cardiology, vol. 112, no. 3, p. 33, 2017.View at: Publisher Site | Google Scholar
F. Paciullo, F. Fallarino, V. Bianconi, M. R. Mannarino, A. Sahebkar, and M. Pirro, “PCSK9 at the crossroad of cholesterol metabolism and immune function during infections,” Journal of Cellular Physiology, vol. 232, no. 9, pp. 2330–2338, 2017.View at: Publisher Site | Google Scholar
B. Ágg, T. Baranyai, A. Makkos et al., “MicroRNA interactome analysis predicts post-transcriptional regulation of ADRB2 and PPP3R1 in the hypercholesterolemic myocardium,” Scientific Reports, vol. 8, no. 1, p. 10134, 2018.View at: Publisher Site | Google Scholar
S. B. Qin, D. Y. Peng, J. M. Lu, and Z. P. Ke, “miR-182-5p inhibited oxidative stress and apoptosis triggered by oxidized low- density lipoprotein via targeting toll-like receptor 4,” Journal of Cellular Physiology, vol. 233, no. 10, pp. 6630–6637, 2018.View at: Publisher Site | Google Scholar